Markets

Diagnostic test developer KineMed files for a $48 million IPO

KineMed, which develops biomarker tests to measure the progression of diseases, filed on Wednesday with the SEC to raise up to $48 million in an initial public offering. The Emeryville, CA-based company, which was founded in 2001 and booked $7 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol KNMD. KineMed initially filed confidentially on November 18, 2013. H.C. Wainwright, MKM Dillon and Dawson James are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs